Certolizumab pegol in active rheumatoid arthritis

Current Rheumatology Reports

Volumn 11, Issue 5, 2009, Pages 311-312

  Patel, Aarat M ^a   Moreland, Larry W ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of Pittsburgh ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; NOTE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT SELECTION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 70449629090     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0056-7     Document Type: Note

References (5)

1. R. Maini E.W. St Clair F. Breedveld, et al. 1999 Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1932 1939 10622295 10.1016/S0140-6736(99)05246-0 1:CAS:528:DC%2BD3cXit1Oquw%3D%3D
2. E.C. Keystone A.F. Kavanaugh J.T. Sharp, et al. 2004 Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis Rheum 50 1400 1411 15146409 10.1002/art.20217 1:CAS:528:DC%2BD2cXkvFykur4%3D (Pubitemid 38608061)
3. S. Schreiber M. Khaliq-Kareemi I.C. Lawrance, et al. 2007 Maintenance therapy with certolizumab pegol for Crohn's disease N Engl J Med 357 239 250 17634459 10.1056/NEJMoa062897 1:CAS:528:DC%2BD2sXotVejs7g%3D (Pubitemid 47080388)
4. J. Smolen R.B. Landewé P. Mease, et al. 2009 Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Ann Rheum Dis 68 797 804 19015207 10.1136/ard.2008.101659 1:CAS:528:DC%2BD1MXotVCjtLo%3D
5. R. Fleischmann J. Vencovsky R. van Vollenhoven, et al. 2009 Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study Ann Rheum Dis 68 805 811 19015206 10.1136/ard.2008.099291 1:CAS:528:DC%2BD1MXotVCjtLs%3D